STOCKS IN THIS WATCHLIST ARE GENERALLY GEARED TOWARDS SWING TRADING BUT CAN ALSO BE USED FOR DAY OR LONG TRADES. STOCKS ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE. ANY TECHNICAL ANALYSIS IS PROVIDED IN THE ACCOMPANYING CHARTS. PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com or wsj.com).
Stocks highlighted in this watchlist include: $KLIC, $SSKN, $ADMA, $SVRA, ACBFF and CMMDF (both OTC)
KLIC: Float of 70.09 million shares with 1.21% short. Momentum increasing toward the end of the day. Down slightly after hours.
Singapore-based Kulicke & Soffa (KLIC) reported earnings per share of 51 cents, up 240% year over year, on sales of $215.9 million, up 48%, in its fiscal fourth quarter ended Sept. 30. Analysts expected earnings of 35 cents a share on sales of $208.7 million. For the current quarter, it expects sales of $190 million, up 27%, based on the midpoint of its guidance. It did not give a target for earnings per share. Wall Street was modeling earnings per share of 17 cents on sales of $160.7 million.
SSKN: Float of 2.47 million shares with 4.85% short. Finviz price target of $12.00.Third quarter total revenues were $7.5 million, a decrease of 3.7% year-over-year;
A medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, reported financial results for the quarter ended September 30, 2017. Third quarter total revenues were $7.5 million, a decrease of 3.7% year-over-year as Recurring revenues were negatively impacted by hurricanes in Florida, Georgia, and Texas. The passing of hurricane season should start to increase Recurring revenues. The hurricanes decrease the stock price by 40% over 4 weeks.
ADMA: Float of 11.92 million shares with 0.92% short.
ADMA Biologics experienced its first full quarter merged with the Biotest Therapy Business Unit (BTBU) and reported 3Q:17 results on November 3, 2017. The main goal and achievement in the quarter was to resume production of Nabi-HB and to make progress addressing the discrepancies in the FDA warning letter.
SVRA: Float of 22.44 million shares with 1.22% short.
Savara Reports Third Quarter 2017 Financial Results and Provides Business Update. Savara's net loss attributable to common shareholders for the three months ended September 30, 2017 was $6.8 million, or $(.28) per share, compared with a net loss attributable to common shareholders of $3.3 million, or $(1.21) per share, for the third quarter of 2016, which represents the historical financial information of the private company Savara Inc., which completed its merger with Mast Therapeutics, Inc. on April 27, 2017.
- Anticipating complete enrollment in the Molgradex Phase 3 IMPALA study in Q1 2018- Initiating Phase 2a study of Molgradex for the treatment of NTM in early 201
- Expecting top-line results from the Aironite Phase 2 INDIE study in H1 2018
Savara Inc., an orphan lung disease company, today announced that the Company's Chief Executive Officer, Rob Neville, will present at the Jefferies 2017 London Healthcare Conference on Thursday, November 16th, 2017 at 12:40 p.m. Greenwich Mean Time.
ACBFF (OTC): Float of 263 million shares and CMMDF Float of 13.7 million shares. Charts for both companies below. This could be hugh.
Aurora Cannabis Inc. (ACB) ("Aurora") announced today that it has submitted a proposal (the "Proposal") to acquire all of the issued and outstanding common shares of CanniMed Therapeutics Inc. (CMED) ("CanniMed"). The proposal was delivered to the Board of Directors of CanniMed on November 13, 2017 and Aurora is seeking to pursue a mutually agreed upon combination with CanniMed.
All-share Proposal, valued at $24.00 per CanniMed share based on the closing share price of Aurora on November 14, 2017, reflects a 56.9% premium over the most recent closing price of CanniMed shares on November 14, 2017 Irrevocable lock-up agreements with approximately 38% of CanniMed shareholders to vote in favour of Aurora's proposal or tender to Aurora's bid -- The combination would create a global leader in the cannabis industry with a pro-forma market capitalization exceeding $3.0 billion --